AI Verdict
RLAY has stronger fundamentals based on our AI analysis.
RLAY vs RKDA Fundamental Comparison
| Metric | RLAY | RKDA |
|---|---|---|
| Revenue | $15.4M | $4.9M |
| Net Income | $-276.5M | $-2.3M |
| Net Margin | -1,800.6% | -48.1% |
| ROE | -48.8% | -56.5% |
| ROA | -44.5% | -35.7% |
| Current Ratio | 22.61x | 3.09x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-1.61 | $-1.71 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RLAY vs RKDA: Frequently Asked Questions
Is RLAY or RKDA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RLAY has stronger fundamentals. RLAY is rated SELL (78% confidence) while RKDA is rated STRONG SELL (90% confidence). This is not investment advice.
How does RLAY compare to RKDA fundamentally?
Relay Therapeutics, Inc. has ROE of -48.8% vs Arcadia Biosciences, Inc.'s -56.5%. Net margins are -1,800.6% vs -48.1% respectively.
Which stock pays higher dividends, RLAY or RKDA?
RLAY has a dividend yield of N/A or no dividend while RKDA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RLAY or RKDA for long term?
For long-term investing, consider that RLAY has SELL rating with 78% confidence, while RKDA has STRONG SELL rating with 90% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RLAY vs RKDA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RLAY vs RKDA, the AI consensus favors RLAY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.